Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab

Pediatric Nephrology

Volumn 28, Issue 5, 2013, Pages 827-830

  Gulleroglu, Kaan ^a   Fidan, Kibriya ^b   Hançer, Veysel S ^c   Bayrakci, Umut ^a   Baskin, Esra ^a   Soylemezoglu, Oguz ^b  

^a BASKENT UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

^c ISTANBUL BILIM UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIINFECTIVE AGENT; CREATININE; ECULIZUMAB; ETIRACETAM; FRESH FROZEN PLASMA; HEMOGLOBIN; MENINGOCOCCUS VACCINE;

ANURIA; ARTICLE; BALANCE DISORDER; CASE REPORT; CHILD; CLONIC SEIZURE; CONFUSION; CREATININE BLOOD LEVEL; DISEASE CONTROL; DISEASE SEVERITY; DNA POLYMORPHISM; ELECTROENCEPHALOGRAM; EXCRETION; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPOALBUMINEMIA; KIDNEY FUNCTION; NYSTAGMUS; OLIGURIA; PALLOR; PATIENT REFERRAL; PERIPHERAL EDEMA; PLASMAPHERESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; SCHOOL CHILD; SINGLE DRUG DOSE; STOMACH PAIN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TONIC CLONIC SEIZURE; TREATMENT DURATION; URINARY TRACT INFECTION; VISUAL IMPAIRMENT; VOMITING; WHITE MATTER LESION;

ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; COMPLEMENT ACTIVATION; CONFUSION; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; NERVOUS SYSTEM DISEASES; NEUROLOGIC EXAMINATION; NYSTAGMUS, PATHOLOGIC; POSTURAL BALANCE; SEIZURES; SENSATION DISORDERS; TREATMENT OUTCOME; VISION DISORDERS;

EID: 84880573893     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-013-2416-9     Document Type: Article

References (15)

1. Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB, European Paediatric Study Group for HUS (2009) Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 24:687-696
2. Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676-1687
3. Neuhaus TJ, Calonder S, Leumann EP (1997) Heterogeneity of atypical haemolyticuraemic syndromes. Arch Dis Child 76:518-521
4. Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, André JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Frémeaux-Bacchi V (2010) Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 21:2180-2187
5. Koehl B, Boyer O, Biebuyck-Gougé N, Kossorotoff M, Frémeaux-Bacchi V, Boddaert N, Niaudet P (2010) Neurological involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol 25:2539-2542
6. Tschumi S, Gugger M, Bucher BS, Riedl M, Simonetti GD (2011) Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. Pediatr Nephrol 26:2085-2088
7. Waters AM, Licht C (2011) aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol 26:41-57
8. Loirat C, Frémeaux-Bacchi V (2011) Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 6:60
9. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G, International Registry of Recurrent and Familial HUS/TTP (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267-1279
10. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V (2012) Use of eculizumab for atypical haemolyticuraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8:643-657
11. Ohanian M, Cable C, Halka K (2011) Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol 3:5-12
12. Gruppo RA, Rother RP (2009) Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 360:544-546
13. Woodruff TM, Ager RR, Tenner AJ, Noakes PG, Taylor SM (2010) The role of the complement system and the activation fragment C5a in the central nervous system. Neuromolecular Med 12:179-192
14. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, Stockman HA, Borchardt JD, Gehrs KM, Smith RJ, Silvestri G, Russell SR, Klaver CC, Barbazetto I, Chang S, Yannuzzi LA, Barile GR, Merriam JC, Smith RT, Olsh AK, Bergeron J, Zernant J, Merriam JE, Gold B, Dean M, Allikmets R (2005) A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 102:7227-7232
15. Vilalta R, Lara E, Madrid A, Chocron S, Muñoz M, Casquero A, Nieto J (2012) Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol 27:2323-2326